1-1 of 1 results for subject:Pfizer
Librarians' tools
- Search time
- 0.222 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the Pfizer BioNTech covid-19 vaccine when there is a 12-week gap between the first and second dose for those aged over 80; and what evidence that assessment is based...
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the Pfizer BioNTech covid-19 vaccine when there is a 12-week gap between the first and second dose for those aged over 80; and what evidence that assessment is based...
Public Health England is monitoring the effectiveness of the COVID-19 vaccines and has published early evidence on the efficacy of both the Pfizer/BioNTech and Oxford/Astrazeneca vaccines. The evidence suggests that a single dose of either vaccine is around 60 to 70% effective at preventing symptomatic disease in older adults and around 80% effective at preventing hospitalisations. There is also evidence that a single dose of the Pfizer/BioNTech vaccine is around 85% effective at preventing deaths. Further information is available at the following link:
https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1
Effectiveness of two doses with a 12-week gap will be monitored as more individuals start to receive their second dose.